Indoco Remedies Share Price

(INDOCO)

Indoco Remedies Limited is a Mumbaibased pharmaceutical company established in 1947 and currently has a presence in 55 countries with a USD 166 million turnover. It mainly focuses on Formulations Finished Dosage Forms and Active Pharmaceutical Ingredients. It is presently active in therapeutic segments, including anti-infective, anti-cold preparation, opthalmic, antispasmodic, stomatology, anti-inflammatory and antifungal. It has 9 manufacturing facilities, 6 for FDFs and 3 for APIs, and is supported by a state-of-the-art RD Centre. AC Nielsen ORGMARG market survey ranks Indoco first in stomatology, ninth in opthalmic and 12th in pediatric segments in terms of prescription generation. It has a marketing network of 1248 medical representatives. To further its goals, the company purchased remaining shares of Xtend Industrial Designers and Engineers in 2014, and acquired a Clinical Research Division from Piramal Enterprise in 2015. It likewise incorporated Indoco Remedies Singapore Pte Limited in 2015 and established a 100% subsidiary in Czech Republic in 2019. It has also launched 8 new products, 5 in Cardiac, 2 in Anti-diabetic and 1 in Dermatology. The company is further patent-recognised for products like Olopatadine, Gliclazide, Brinzolamide, Febuxostat, Rufinamide, Lacosamide, Tapentadol, Aminoindane compound and Pyrazole derivatives. It currently has 3 subsidiary companies under its fold, Xtend Industrial Designers and Engineers Pvt. Ltd., Indoco Remedies Czech sro and Indoco Remedies UK Limited.

Share Price: ₹248.45 per share as on 29 Jan, 2025 04:01 PM
Market Capitalisation: ₹2,280.13Cr as of today
Revenue: ₹402.45Cr as on December 2024 (Q4 24)
Net Profit: ₹-28.40Cr as on December 2024 (Q4 24)
Listing date: 14 Jan, 2005
Chairperson Name: Suresh G Kare